Literature DB >> 2201821

Interleukin 2 receptors.

M Allouche1, Y Sahraoui, Y Augery-Bourget, M Perrakis, C Jasmin, V Georgoulias.   

Abstract

Interleukin 2 receptors (IL-2-R) are composed of (at least) two chains: the alpha chain (or p55 or Tac) and the beta chain (or p70 or p75). The association of both chains constitutes high affinity IL2-R complexes (Kd congruent to 10-100 pM), whereas the alpha-chain or the beta chain alone bind IL-2 with low (Kd congruent to 5-50 nM) and intermediate (Kd congruent to 1 nM) affinities, respectively. The beta chain (but not the alpha chain) mediates IL-2 internalization and signal transduction (proliferation or differentiation) to the cell, thus only high and intermediate affinity IL-2-R are functional. High affinity IL-2-R are expressed on activated normal and leukemic T and B lymphoid cells. Low affinity IL-2-R (Tac alone) are seen on stimulated T cells, B cells, and monocytes, as well as on various leukemic cells. The p70 chain alone is constitutively expressed by subsets of normal resting T and B cells, LGL and NK cells and we have recently demonstrated its presence on leukemic cells from various hemopoietic lineages. The finding of IL-2-R on non-lymphoid cells may disclose new functions for IL-2.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2201821     DOI: 10.1016/0145-2126(90)90097-s

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  4 in total

1.  Interleukin-2 receptor expression on blood monocytes of patients with multiple sclerosis.

Authors:  M Zaffaroni; A Ghezzi; L Callea; A Zibetti
Journal:  Ital J Neurol Sci       Date:  1992-11

2.  Hematopoietic chimerism and central tolerance created by peripheral-tolerance induction without myeloablative conditioning.

Authors:  Edward Seung; John P Mordes; Aldo A Rossini; Dale L Greiner
Journal:  J Clin Invest       Date:  2003-09       Impact factor: 14.808

3.  Multiparametric analyses of human PBMCs loaded ex vivo with a candidate idiotype vaccine for HCV-related lymphoproliferative disorders.

Authors:  Annacarmen Petrizzo; Maria Lina Tornesello; Maria Napolitano; Giovanna D'Alessio; Angelo Salomone Megna; Riccardo Dolcetti; Valli De Re; Ena Wang; Franco M Marincola; Franco M Buonaguro; Luigi Buonaguro
Journal:  PLoS One       Date:  2012-09-18       Impact factor: 3.240

4.  Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses.

Authors:  R P Sutmuller; L M van Duivenvoorde; A van Elsas; T N Schumacher; M E Wildenberg; J P Allison; R E Toes; R Offringa; C J Melief
Journal:  J Exp Med       Date:  2001-09-17       Impact factor: 14.307

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.